Citations

Clear

904 citation(s) found for "Gordon, S".

Percentage of Smudge Cells on Routine Blood Smear Predicts Survival in Chronic Lymphocytic Leukemia
Nowakowski, Grzegorz S. , Hoyer, James D., Call, Timothy G. , Bone, Nancy D., LaPlant, Betsy, Dewald, Gordon W., Tschumper, Renee C. , Jelinek, Diane F., Shanafelt, Tait D. , Zent, Clive S. , Witzig, Thomas E. , Kay, Neil E.

Mayo Clinic

Journal of Clinical Oncology | March 3, 2009 | Volume: 27 | Issue: 11 | Pages: 1844-1849

10.1200/jco.2008.17.0795 | PMID 19255329 Get It

PurposeSmudge cells are ruptured chronic lymphocytic leukemia (CLL) cells appearing on the blood smears of CLL patients. Our recent findings suggest that the number of smudge cells may have important biologic correlations rather than being only an artifact of slide preparation. In this study, we evaluated whether the smudge cell percentage on a blood smear predicted survival of CLL patients.Patients and MethodsWe calculated smudge cell percentages (ratio of smudged to intact cells plus smudged lymphocytes) on archived blood smears from a cohort of previously untreated patients with predominantly early-stage CLL enrolled onto a prospective observational study. The relationship between percentage of smudge cells, patient survival, and other prognostic factors was explored.ResultsBetween 1994 and 2002, 108 patients were enrolled onto the study and had archived blood smears available for review; 80% of patients had Rai stage 0 or I disease. The median smudge cell percentage was 28% (range, 1% to 75%). The percentage of smudge cells was lower in CD38+versus CD38–patients (P = .019) and in Zap70-positive versus Zap70-negative patients (P = .028). Smudge cell percentage as a continuous variable was associated with prolonged survival (P = .042). The 10-year survival rate was 50% for patients with 30% or less smudge cells compared with 80% for patients with more than 30% of smudge cells (P = .015). In multivariate analysis, the percentage of smudge cells was an independent predictor of overall survival.ConclusionPercentage of smudge cells on blood smear is readily available and an independent factor predicting overall survival in CLL.
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Tr
Rowe, Jacob M. , Richards, Susan , Buck, Georgina , Moorman, Anthony V. , Durrant, Ian, Marks, David I. , McMillan, Andrew , Litzow, Mark R. , Foroni, Letizia, Dewald, Gordon W., Franklin, Ian M., Luger, Selina M. , Paietta, Elisabeth , Wiernik, Peter H. , Tallman, Martin S. , Goldstone, Anthony H., Fielding, Adele K. , Lazarus, Hillard M. , Franklin, Ian M.

Mayo Clinic

Blood | February 25, 2009 | Volume: 113 | Issue: 19 | Pages: 4489-4496

10.1182/blood-2009-01-199380 | PMID 19244158 Get It

Abstract Prospective data on the value of allogeneic hematopoietic stem cell transplantation (alloHSCT) in Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) are limited. The UKALLXII/ECOG 2993 study evaluated the outcome of assigning alloHSCT with a sibling (sib) or matched unrelated donor (MUD) to patients younger than 55 years of age achieving complete remission (CR). The CR rate of 267 patients, median age 40, was 82%. Twenty-eight percent of patients proceeded to alloHSCT in first CR. Age older than 55 years or a pre-HSCT event were the most common reasons for failure to progress to alloHSCT. At 5 years, overall survival (OS) was 44% after sib alloHSCT, 36% after MUD alloHSCT, and 19% after chemotherapy. After adjustment for sex, age, and white blood count and excluding chemotherapy-treated patients who relapsed or died before the median time to alloHSCT, only relapse-free survival remained significantly superior in the alloHSCT group (odds ratio 0.31, 95% confidence interval 0.16-0.61). An intention-to-treat analysis, using the availability or not of a matched sibling donor, showed 5-year OS to be nonsignificantly better at 34% with a donor versus 25% with no donor. This prospective trial in adult Ph+ ALL indicates a modest but significant benefit to alloHSCT. This trial has been registered with clinicaltrials.gov under identifier NCT00002514 and as ISRCTN77346223.
Double blind, you have been voted off the island!
Devereaux, P.J. , Bhandari, Mohit , Montori, Víctor M. , Manns, Braden , Ghali, William A., Guyatt, Gordon , Montori, Victor M

Mayo Clinic

Evidence Based Mental Health | December 31, 2008 | Volume: 5 | Issue: 2 | Pages: 36-37

10.1136/ebmh.5.2.36 Get It

Gasping During Cardiac Arrest in Humans Is Frequent and Associated With Improved Survival
Bobrow, Bentley J., Zuercher, Mathias, Ewy, Gordon A. , Clark, Lani, Chikani, Vatsal , Donahue, Dan, Sanders, Arthur B., Hilwig, Ronald W., Kern, Karl B. , Berg, Robert Allen

Mayo Clinic

Circulation | November 24, 2008 | Volume: 118 | Issue: 24 | Pages: 2550-2554

10.1161/circulationaha.108.799940 | PMID 19029463 Get It

Background— The incidence and significance of gasping after cardiac arrest in humans are controversial. Methods and Results— Two approaches were used. The first was a retrospective analysis of consecutive confirmed out-of-hospital cardiac arrests from the Phoenix Fire Department Regional Dispatch Center text files to determine the presence of gasping soon after collapse. The second was a retrospective analysis of 1218 patients with out-of-hospital cardiac arrests in Arizona documented by emergency medical system (EMS) first-care reports to determine the incidence of gasping after arrest in relation to the various EMS arrival times. The primary outcome measure was survival to hospital discharge. An analysis of the Phoenix Fire Department Regional Dispatch Center records of witnessed and unwitnessed out-of-hospital cardiac arrests with attempted resuscitation found that 44 of 113 (39%) of all arrested patients had gasping. An analysis of 1218 EMS-attended, witnessed, out-of-hospital cardiac arrests demonstrated that the presence or absence of gasping correlated with EMS arrival time. Gasping was present in 39 of 119 patients (33%) who arrested after EMS arrival, in 73 of 363 (20%) when EMS arrival was <7 minutes, in 50 of 360 (14%) when EMS arrival time was 7 to 9 minutes, and in 25 of 338 (7%) when EMS arrival time was >9 minutes. Survival to hospital discharge occurred in 54 of 191 patients (28%) who gasped and in 80 of 1027 (8%) who did not (adjusted odds ratio, 3.4; 95% confidence interval, 2.2 to 5.2). Among the 481 patients who received bystander cardiopulmonary resuscitation, survival to hospital discharge occurred among 30 of 77 patients who gasped (39%) versus only 38 of 404 among those who did not gasp (9%) (adjusted odds ratio, 5.1; 95% confidence interval, 2.7 to 9.4). Conclusions— Gasping or abnormal breathing is common after cardiac arrest but decreases rapidly with time. Gasping is associated with increased survival. These results suggest that the recognition and importance of gasping should be taught to bystanders and emergency medical dispatchers so as not to dissuade them from initiating prompt resuscitation efforts when appropriate.
In Reply
Djulbegović, Benjamin , Montori, Víctor M. , Wilcox, Ryan A. , Guyatt, Gordon , Montori, Victor M

Mayo Clinic

Journal of Clinical Oncology | May 28, 2008 | Volume: 26 | Issue: 16 | Pages: 2788-2788

10.1200/jco.2008.17.2478 Get It

Karyotype Evolution on Fluorescent In Situ Hybridization Analysis Is Associated With Short Survival in Patients With Chronic Lymphocytic Leukemia and Is Related to CD49d Expression
Hanson, Curtis A. , Dewald, Gordon W., LaPlant, Betsy, Abrahamzon, Jennifer L., Jelinek, Diane F., Shanafelt, Tait D. , Witzig, Thomas E. , Kay, Neil E.

Mayo Clinic

Journal of Clinical Oncology | May 8, 2008 | Volume: 26 | Issue: 14 | Pages: e5-e6

10.1200/jco.2008.16.7874 | PMID 18467710 Get It

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
Adjei, Alex A. , Cohen, Roger B. , Franklin, Wilbur A., Morris, Clive, Wilson, David M. , Molina, Julian R. , Hanson, Lorelei J., Gore, Lia , Maloney, Lara , Gordon, Gilad S., Simmons, Heidi, Marlow, Allison, Litwiler, Kevin , Brown, Suzy, Pöch, G, Kane, Katie, Haney, Jerry, Chow, Laura Q.M. , Leong, Stephen , Eckhardt, Sabine

Mayo Clinic

Journal of Clinical Oncology | April 8, 2008 | Volume: 26 | Issue: 13 | Pages: 2139-2146

10.1200/jco.2007.14.4956 | PMID 18390968 Get It

Purpose To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer. Patients and Methods In part A, patients received escalating doses to determine the maximum-tolerated dose (MTD). In both parts, blood samples were collected to assess PK and PD parameters. In part B, patients were stratified by cancer type (melanoma v other) and randomly assigned to receive the MTD or 50% MTD. Biopsies were collected to determine inhibition of ERK phosphorylation, Ki-67 expression, and BRAF, KRAS, and NRAS mutations. Results Fifty-seven patients were enrolled. MTD in part A was 200 mg bid, but this dose was discontinued in part B because of toxicity. The 50% MTD (100 mg bid) was well tolerated. Rash was the most frequent and dose-limiting toxicity. Most other adverse events were grade 1 or 2. The PKs were less than dose proportional, with a median half-life of approximately 8 hours and inhibition of ERK phosphorylation in peripheral-blood mononuclear cells at all dose levels. Paired tumor biopsies demonstrated reduced ERK phosphorylation (geometric mean, 79%). Five of 20 patients demonstrated ≥ 50% inhibition of Ki-67 expression, and RAF or RAS mutations were detected in 10 of 26 assessable tumor samples. Nine patients had stable disease (SD) for ≥ 5 months, including two patients with SD for 19 (thyroid cancer) and 22 (uveal melanoma plus renal cancer) 28-day cycles. Conclusion AZD6244 was well tolerated with target inhibition demonstrated at the recommended phase II dose. PK analyses supported twice-daily dosing. Prolonged SD was seen in a variety of advanced cancers. Phase II studies are ongoing.
Origins and Prevalence of the American Founder Mutation of MSH2
Baze, Mark E., Walsh, Kyle M. , Liyanarachchi, Sandya , Fix, Dan, Schunemann, Victoria , Comeras, Ilene, Deacon, Molly, Lynch, Jane F., Gong, Gordon, Thomas, Brittany C. , Thibodeau, Stephen N. , Lynch, Henry T., Chapelle, Albert de la , Clendenning, Mark , Sun, Shuying , Hampel, Heather

Mayo Clinic

Cancer Research | April 1, 2008 | Volume: 68 | Issue: 7 | Pages: 2145-2153

10.1158/0008-5472.can-07-6599 | PMID 18381419 Get It

Abstract Large germline deletions within the mismatch repair gene MSH2 account for a significant proportion (up to 20%) of all deleterious mutations of this gene which are associated with Lynch syndrome. An exons 1 to 6 deletion of MSH2, originally reported in nine families, has been associated with a founding event within the United States, which genealogic studies had previously dated to 1727, and the number of present day carriers was estimated to be 18,981. Here, we report the development of a robust multiplex PCR which has assisted in the detection of 32 new families who carry the MSH2 American Founder Mutation (AFM). By offering testing to family members, 126 carriers of the AFM have been identified. Extensive genealogic studies have connected 27 of the 41 AFM families into seven extended pedigrees. These extended families have been traced back to around the 18th century without any evidence of further convergence between them. Characterization of the genomic sequence flanking the deletion and the identification of a common disease haplotype of between 0.6 and 2.3 Mb in all probands provides evidence for a common ancestor between these extended families. The DMLE+2.2 software predicts an age of ∼500 years (95% confidence interval, 425–625) for this mutation. Taken together, these data are suggestive of an earlier founding event than was first thought, which likely occurred in a European or a Native American population. The consequences of this finding would be that the AFM is significantly more frequent in the United States than was previously predicted. [Cancer Res 2008;68(7):2145–53]
Genetic and Clinical Heterogeneity in eIF2B-Related Disorder
Maletkovic, Jelena , Gorospe, J. Rafael, Gordon, Erynn S. , Mintz, Michelle, Hoffman, Eric P. , Alper, Gülay, Singhal, Bhim , Amartino, Hernán , Brown, Candida, Chan, Alicia , Renaud, Deborah L. , Geraghty, Michael T. , Jensen, Lloyd, Şenbil, Nesrin , Kadom, Nadja , Nazarian, Javad , Feng, Yuanjian, Wang, Zuyi, Morizono, Hiroki , Vanderver, Adeline , Schiffmann, Raphael , Lynch, David R. , Harding, Cary O. , Hartka, Thomas , Nazarian, Javad

Mayo Clinic

Journal of Child Neurology | February 8, 2008 | Volume: 23 | Issue: 2 | Pages: 205-215

10.1177/0883073807308705 | PMID 18263758 Get It

Eukaryotic initiation factor 2B (eIF2B)-related disorders are heritable white matter disorders with a variable clinical phenotype (including vanishing white matter disease and ovarioleukodystrophy) and an equally heterogeneous genotype. We report 9 novel mutations in the EIF2B genes in our subject population, increasing the number of known mutations to more than 120. Using homology modeling, we have analyzed the impact of novel mutations on the 5 subunits of the eIF2B protein. Although recurrent mutations have been found at CpG dinucleotides in the EIF2B genes, the high incidence of private or low frequency mutations increases the challenge of providing rapid genetic confirmation of this disorder, and limits the application of EIF2B screening in cases of undiagnosed leukodystrophy.
Repeated fracture of a vertebral body after treatment with balloon kyphoplasty
Leslie‐Mazwi, Thabele M , Deen, H. Gordon

Mayo Clinic

Journal of Neurosurgery: Spine | January 24, 2008 | Volume: 4 | Issue: 3 | Pages: 270

10.3171/spi.2006.4.3.270 | PMID 16572630 Get It